rney's Docket No.: 07064-009002 Applicant: Rajesh Kumar, et al.

Serial No.: 09/940,235 : August 27, 2001 Filed

Page

3 of 14

## In the claims:

## Please amend the claims as follows:

(Currently Amended) A hybrid plasminogen activator comprising a single 1. polypeptide molecule having the following components bond union between:

- a plasminogen activating component comprising a streptokinase (SK), or a <u>a)</u> modified forms of SK, or suitable parts thereof, portions of a SK which are capable of plasminogen activation, with and
- a fibrin binding component comprising regions of human fibronectin b) selected from the pair of fibrin binding domains 4 and 5, or domains 1 and 2, or modified forms thereof, to achieve various motifs for joining the fibrin binding domains with streptokinase or its modified forms, so that

the hybrid plasminogen activator possessesing the ability to bind with fibrin independently, and also characteristically retains a exhibiting plasminogen activation ability which becomes evident only after a pronounced duration, or lag in comparison to plasminogen activation by the plasminogen activating component alone, after exposure of the plasminogen activator to a suitable animal or human plasminogen.

- 2. (Currently Amended) A hybrid plasminogen activator as claimed in Claim 1, wherein the plasminogen activating component streptokinase molecule binds is bound with the fibrin binding regions of human fibronectin, selected from the pair pari of fibrin binding domains 4 and 5, domains 1 and 2 or modifications thereof, as depicted in Figure 1.
- (Currently Amended) A hybrid plasminogen activator as claimed in Claim 1 3. which carries out plasminogen activation only after a lag period varying between 5 and 30 minutes after exposure of the plasminogen activator to a suitable animal or human plasminogen.

Claims 4-31 (Cancelled)

Applicant: Rajesh Kumar, et al.

Serial No. : 09/940,235 Filed : August 27, 2001

Page

: 4 of 14

32. (Currently Amended) A pharmaceutical composition comprising the hybrid plasminogen activator according to claim 1 and a hybrid stabilizers such as human serum albumin, mannitol etc. agents].

Anorney's Docket No.: 07064-009002